Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Proprietary resveratrol in tests

This article was originally published in The Tan Sheet

Executive Summary

Sirtris Pharmaceuticals' SRT501 resveratrol-containing drug was safe, well-tolerated and "significantly" lowered glucose in an oral glucose tolerance test conducted as part of a 28-day Phase 1b clinical study in patients with type 2 diabetes, which is the first human study of the drug, the Cambridge, Mass.-based biopharmaceutical firm says Jan. 7. The study was designed to assess the safety, tolerability and pharmacokinetics of once-daily, orally administered doses of 2.5 g or 5 g of SRT501, which contains the firm's proprietary resveratrol substance, in type 2 diabetes patients. Pharmacokinetic levels, a measure of drug levels in the blood, were identical at days one and 28, suggesting no drug accumulation. SRT501 showed a statistically significant improvement in an oral glucose tolerance test on day 28 at two hours and a trend toward lower fasting plasma glucose levels. Natural resveratrol is a phytoalexin found in the skin of red grapes and is generating interest as a supplement ingredient (1"The Tan Sheet" Nov. 26, 2007, p. 13)...

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts